Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTO-3712 in Healthy Volunteers and Atopic Dermatitis
NCT07205081Phase 1Completed
- Sponsor
- Attovia Therapeutics
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ATTO-3712 in atopic dermatitis (AD) (6 arms), sponsored by Attovia Therapeutics. Primary endpoints: Incidence of Adverse Events at 143 days, Incidence of laboratory abnormalities at 143 days and 2 more. Started Oct 2025; status: completed.
02
Drugs
ATTO-3712
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07205081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205081.